MiniMed Group Reports 16.6% Revenue Growth to $843 Million for Quarter Ended July 31, 2026

MiniMed Group, Inc. reported a significant increase in financial performance for the three months ended July 31, 2026, with net sales reaching $843 million, up from $723 million in the same period last year, marking a growth of 16.6%. The company's gross profit also rose to $465 million, compared to $409 million in the prior year, reflecting a gross margin of 55.1%. Despite these gains, MiniMed reported a net loss of $0 for the quarter, a notable improvement from a loss of $16 million in the previous year. The company attributed this positive shift to increased sales volumes, particularly in its insulin pump and continuous glucose monitoring (CGM) segments.

The company experienced notable changes in its operational metrics, with new pump sales increasing to 34,000 units from 32,000 units year-over-year. The global CGM attachment rate also improved, rising from 64% to 69%. This growth was driven by the successful launch of the MiniMed Flex insulin pump and the Instinct CGM sensor, which contributed to a 20% increase in CGM sales. International sales saw an 18% increase, while U.S. sales grew by 13%, benefiting from the additional week of sales in the current fiscal period.

Strategically, MiniMed has made significant advancements since its separation from Medtronic in March 2026. The company launched the MiniMed Go Smart MDI system in Europe and initiated the U.S. launch of the MiniMed Flex in August 2026. Additionally, a partnership with Abbott Laboratories was extended to integrate dual glucose-ketone sensors with MiniMed's smart dosing systems, expected to enhance product offerings in 2027. The company is also preparing for the FDA submission of the MiniMed Fit patch pump, with a full launch anticipated in Summer 2027.

Financially, MiniMed's operating expenses increased to $465 million, driven by higher selling, general, and administrative costs, which rose by 10.4% to $312 million. Research and development expenses decreased by 7.8% to $115 million, reflecting a strategic focus on cost management. The company reported a cash balance of $207 million as of July 31, 2026, with no long-term debt outstanding, and it maintains a revolving credit facility of up to $500 million. Looking ahead, MiniMed anticipates continued growth driven by product innovation and market expansion, despite facing challenges such as pricing pressures in the CGM market and the need for ongoing investment in its product pipeline.